Hobbs F D, Kenkre J E, Carter Y H, Thorpe G H, Holder R L
Department of General Practice, Medical School, University of Birmingham.
Br J Gen Pract. 1996 Jul;46(408):395-400.
The applications of new diagnostic technologies such as near patient tests are relevant to the further development and potential of primary care. Through their use, doctors in the community may increase the accuracy of their diagnoses and improve their ability to monitor disease. A reliable indicator of disease activity in various clinical conditions is C-reactive protein (CRP) and a near patient test for this is now available, although there is little information on its use outside hospitals.
A study was set up to evaluate the feasibility of using a novel near patient test for CRP in primary care to validate the results against the laboratory "gold standard' for CRP (Beckman Array) and to compare results with the usual inflammation test used in general practice.
Prospective recording of CRP as a near patient test on an "intention to investigate' basis, with validation of results against the Beckman Array system for CRP and hospital laboratory erythrocyte sedimentation rate results, in six general medical practices in Birmingham. Main outcome measures were change in local laboratory usage, characteristics of patients chosen for testing, use of quality control, and comparison of readings with results from the same sample sent to an independent laboratory.
Tests of CRP levels were rarely requested before the study was undertaken. During the 3-month study period, 181 near patient tests were carried out, 146 (81%) to establish a diagnosis and the remainder for disease monitoring. Out of the tests, 67% were performed by general practitioners, mostly during the consultation itself. Using a cut-off level of 10 mg I-1, the near patient test and the Beckman Array gave results which agreed in 84% of cases. The sensitivity and specificity of the near patient test results were 97 and 79%, respectively. The predictive value of a positive result was 59% and that of a negative result was 99%. Cohen's Kappa was 62% and the overall mean bias for results in the range of the test was 6.11 mg I-1 (SE = 3.07 mg I-1). Each test took 6 min on average to perform, including all preparations, blood letting, performing the test and averaging the time for quality control estimations. The cost per test averaged pounds 1.72, rising to pounds 4.17 including labour, capital costs, quality controls and consumables (general practitioner performing the assay at average frequency found in this study).
Measurement of CRP is rarely used in primary care and awareness of its value could be raised. This near patient test proved feasible for use by general practitioners and practice nurses. Its reliability compared with a laboratory result was satisfactory overall, and excellent with adequate operator technique.
近患者检测等新诊断技术的应用与初级医疗保健的进一步发展及潜力相关。通过使用这些技术,社区医生可提高诊断准确性并增强疾病监测能力。C反应蛋白(CRP)是各种临床病症中疾病活动的可靠指标,目前已有针对CRP的近患者检测方法,不过关于其在医院外使用的信息较少。
开展一项研究,以评估在初级医疗保健中使用新型CRP近患者检测的可行性,将结果与CRP的实验室“金标准”(贝克曼检测系统)进行验证,并与全科医疗中常用的炎症检测结果进行比较。
在伯明翰的6家普通医疗诊所,以前瞻性方式记录CRP近患者检测结果,检测基于“调查意向”进行,将结果与贝克曼CRP检测系统以及医院实验室红细胞沉降率结果进行验证。主要观察指标包括当地实验室检测使用情况的变化、选择进行检测的患者特征、质量控制的使用情况,以及将读数与送往独立实验室的同一样本的结果进行比较。
在开展该研究之前,很少有人要求检测CRP水平。在为期3个月的研究期间,共进行了181次近患者检测,其中146次(81%)用于确诊,其余用于疾病监测。在这些检测中,67%由全科医生进行,大多是在诊疗过程中。使用10mg/L的临界值,近患者检测和贝克曼检测系统在84%的病例中结果一致。近患者检测结果的敏感性和特异性分别为97%和79%。阳性结果的预测值为59%,阴性结果的预测值为99%。科恩kappa系数为62%,检测范围内结果的总体平均偏差为6.11mg/L(标准误=3.07mg/L)。每次检测平均耗时6分钟,包括所有准备工作、采血、进行检测以及计算质量控制估计的平均时间。每次检测平均成本为1.72英镑,包括人工、资本成本、质量控制和耗材后升至4.17英镑(全科医生按本研究中发现的平均频率进行检测)。
CRP检测在初级医疗保健中很少使用,可提高对其价值的认识。这种近患者检测方法被证明对全科医生和执业护士可行。与实验室结果相比,其可靠性总体令人满意,在操作人员技术熟练的情况下表现出色。